Gummies Week · UP TO 75% OFF UP TO 75% OFF · Gummies Week Ends in This week only · 76 gummies picks marked down Shop the deals →
Go back
Refer for $20
$20
Refer
Get $20 in Chowcash when you refer friends, stores, and brands to Chow420. Your friends also get $20 towards their first purchase when they accept your invitation.
Login to Refer

Hemp News, Laws & Product Updates

A curated news hub focused on hemp regulation and policy changes, cannabinoids (CBD/Delta-8/Delta-9/hemp-derived THC), lab testing and COAs, product safety, brands, and industry trends.

  • Federal & State Hemp Laws
  • THC Policy
  • CBD / Delta-8
  • Compliance
  • Lab Testing (COA)
  • Product Safety
  • Industry & Brands
Back to Chow420
https://hightimes.com/

Minnesota Senate Approves Bill To Accelerate Licensing of Weed Businesses

The Minnesota state Senate last week approved a bill to accelerate the licensing of cannabis businesses, narrowly approving the measure by a vote of 34-32. If passed by the legislature and signed into law, the legislation would set the stage for cultivators to begin growing regulated weed by the end of the year. Minnesota lawmakers passed legislation to legalize recreational marijuana in May 2023, with provisions allowing adults to possess up to two ounces of cannabis in a public place and up to two pounds of weed at home beginning on August 1 of last year. The measure also allows adults to grow up to eight cannabis plants at home, including four mature, flowering plants. The bill also legalized the cultivation and sale of regulated cannabis by licensed businesses, with dispensary sales of recreational marijuana anticipated to start in January 2025. Under legislation passed by the Minnesota Senate on Friday, state regulators would be able to issue preliminary approval for cannabis cultivators beginning this summer. Supporters of the bill say the legislation will allow prospective regulated cultivators to line up funding for their operations, secure a business location and complete other tasks related to launching their business. “This newly regulated, legalized and regulated industry is in its infancy, and we’re here to continue the work we started last year,” said Democratic Senator Lindsey Port, according to a report from the Albert Lea Tribune. “Like any new industry, it will not be fully grown on day one. This bill works to ensure a successful market launch and support the industry and Minnesotans involved in this industry as it grows and develops.” The legislation also tasks the Minnesota Office of Cannabis Management with regulating hemp-derived cannabinoids and medical marijuana, which are currently regulated by the state Department of Health. The office recommended many of the provisions of the bill to help facilitate the timely transition to regulated sales of recreational marijuana. Under the bill, companies given early approval to grow adult-use cannabis would temporarily be subject to the state’s existing rules for medical marijuana cultivation until the Office of Cannabis Management finalizes recreational marijuana regulations later this year. The bill was opposed by many Republican lawmakers who expressed concerns that establishing temporary regulations that might vary from the forthcoming permanent rules could be problematic. They also balked at allowing businesses to begin growing recreational weed before they are licensed by the state. “I understand that there are folks that want to have the cannabis industry open and running today,” said Republican Senator Jordan Rasmusson. “But I think for the health and safety of Minnesotans for public safety, for just regulatory integrity, and an open and transparent process that would allow Minnesotans to engage on rulemaking, it’s really important that we don’t do an end-around.” Opponents of the bill are concerned that accelerating the pace to approve regulated cultivators could lead to unintended consequences. The also were concerned about cannabis being obtained by young people and proposed an amendment that would make possession of weed by minors a misdemeanor criminal offense. “How can we say it’s wrong and a petty misdemeanor or maybe even a misdemeanor for repeat offenses for a child to be drinking a beer, but it’s okay for them to be walking down the street with a bag of marijuana or smoking a joint?” said Senator Eric Pratt. “Where’s the consistency in that?” Democratic Governor Tim Walz said that he is monitoring developments in the legislation and noted that he is aware that some people are not comfortable with the prospect of allowing cultivation to begin by the end of the year, stressing that the regulations must include quality standards for cannabis cultivators. “We certainly hear people on this. I think there’s some potential there,” Walz told reporters earlier this week. “We’re trying the best we can, but we’re not going to cut corners.” The bill was approved with amendments by the Minnesota House of Representatives last month. The legislation will now head to a conference committee, where lawmakers from both chambers of the legislature will reconcile differences between the two versions of the amended bill.

https://hightimes.com/

Some NY Lawmakers Say Illicit Pot Shops Must Close Before Adding Licensed Shops

After officially legalizing cannabis for adult use in New York, the journey that followed has been fairly tumultuous as multiple roadblocks have delayed shop licensure and hindered the legal industry’s full potential. A number of lawsuits and a change in gubernatorial leadership delayed dispensary licensure and openings, in turn allowing the illicit market to flourish with those shops drastically outnumbering the amount of legal dispensaries in the state. As New York growers, business owners and myriad cannabis professionals continue to wait for their licenses to be approved, some New York lawmakers are embracing a different approach (that would likely extend the wait for industry hopefuls even longer). Namely, Queens Community Board 9 Chairwoman Sherry Algredo argued that New York should refrain from adding any licensed cannabis shops to her district until authorities are able to shut down those operating illegally, according to a New York Post report. Community Board 9 covers the neighborhoods Key Gardens, Richmond Hill, Ozone Park and Woodhaven. “The Board received numerous concerns from residents regarding the proliferation of illegal smoke shops already operating in our district and the negative impact these establishments have had on our community,” Algredo said in a recent letter. “Consequently, the Board will not support any new applications until these illegal operations are shut down.” While Algredo’s statement reads as fairly definitive, the boards’ recommendations are advisory to state regulators, though they can still influence final policy decisions. The law that legalized cannabis in New York also mandates that applicants for cannabis licenses must notify the community board within the vicinity they plan to operate and appear before it prior to opening their businesses. The conversation surrounding illicit cannabis shops in New York has been ongoing, though Gov. Kathy Hochul (D) and other lawmakers have consistently touted their efforts to mitigate theses problems. In April, the governor unveiled new initiatives aimed to shut down illicit cannabis operations and protect the legal cannabis marketplace. The plan allows the Office of Cannabis Management and local municipalities new authority to take action against illicit shops.  “Unlicensed dispensaries have littered New York neighborhoods, blatantly circumventing our laws and selling potentially dangerous products,” Hochul said in a statement. “Enough is enough. I promised to protect our communities and hard-working, legal cannabis licensees by expediting the closure of illicit storefronts. I’m proud to stand up and say we got it done.” Last month also marked the opening of the 100th adult-use store in the state. New York legalized adult-use cannabis on March 31, 2021. It also looks like that number should increase soon, as the New York State Cannabis Control Board (CCB) shared last month that it approved an additional 101 adult-use cannabis licenses with more than 400 total approved sites in 2024.  Conversely, it’s estimated that New York City alone has about 2,000 illicit cannabis stores currently operating. The state is still working to do what it can to fix the issues with the legal industry rollout. Lawmakers recently passed another resolution that gives the Office of Cannabis Management (OCM) the ability to issue provisional licenses, which the CCB hopes will speed up the licensing process.  “This measure aims to provide provisional license holders with opportunities to begin operations swiftly while adhering to regulatory requirements, fostering a dynamic and competitive marketplace,” the CCB explained. Still, it’s clear that closing illicit pot shops in the state will not be an easy task. Many illicit shops immediately reopened after raids and temporary shutdown orders under the prior rules, and it’s not yet clear how effective the newly announced laws to close illegal shops will be in practice. Because of that, closing all illicit shops before allowing new ones to open, even in a single district, may be tougher in reality than in theory. Still, some lawmakers are standing by the need to close unlicensed shops before adding more licensed ones. “We have 32 illegal cannabis shops. We are not going to entertain any applications for legal cannabis shops until the unlicensed stores are shut down,” CB 9 District Manager James McClelland told The Post.

https://hightimes.com/

Study: ADHD Patient MMJ Use Leads to Improvements in Anxiety, Sleep, Quality of Life

When it comes to medical benefits, cannabis is often associated with its anti-inflammatory, pain-relieving and sedative properties. But given the versatile nature of the plant, researchers are looking beyond some of the more common qualifying medical conditions to uncover the full medicinal potential of cannabis.  Though it’s largely under-researched, it’s possible that cannabis could work to help folks with attention deficit/hyperactivity disorder (ADHD) to better manage their symptoms. A recent observational study published in the journal Neuropsychopharmacology Reports found that, indeed, medical cannabis may be beneficial for people with ADHD — though not necessarily for reasons associated with focus and attention. Rather, researchers found that cannabis use led to observed improvements in the anxiety, sleep quality and health-related quality of life among participants. While the results are not definitive, authors argue that the findings are substantial enough to hopefully prompt future research on cannabis and ADHD. The team of UK-based researchers aimed to primarily assess the health-related quality of life and safety outcomes in ADHD patients treated with cannabis-based medicinal products (CBMPs). ADHD has an estimated global prevalence of 5% in children and 2.5% in adults, with estimated incidences of ADHD diagnosis increasing by approximately 42% in children between 2003 and 2011 and 123% in adults between 2007 and 2016 in the U.S., according to the study. ADHD is a neurodevelopmental condition generally associated with issues with focus, hyperactivity, impulsivity and/or psychosocial differences in managing relationships. ADHD is also associated with a higher instance of sleep disturbance and co-morbidities like anxiety and depression.  It falls under the neurodivergent umbrella, characterized as a natural variation in how the human brain processes information. Researchers note that current treatment for ADHD consists of a combination of psychological therapies and both stimulant and non-stimulant medications. However, they note that stimulant medications may come with unwanted side effects, while non-stimulant medications can similarly result in adverse effects that may hinder people from taking them on a long-term basis. They note that the endocannabinoid system, which cannabinoids like THC and CBD interact with directly, plays a vital role in cognitive function, motor coordination and homeostasis,” suggesting that medical cannabis could be useful in treating symptoms associated with ADHD. In order to examine how cannabis use can impact people with ADHD, researchers tracked data on 68 patients from the UK Medical Cannabis Registry (UKMCR) and patient-recorded outcome measures at one, three, six and 12 months from baseline. Eighty percent of the participants already consumed cannabis at the point of initiating treatment. At each followup, patients answered surveys regarding severity of generalized anxiety disorder symptoms, sleep quality and health-related quality of life. Ultimately, researchers found that all three elements had improved over time. Specifically, anxiety and sleep quality metrics showed improvement at each check-in over the observed year. Researchers also observed significant improvements in health-related quality of life during the first six months of the study, but by the 12th month there was no difference between those who were current consumers and those who were not. Just 11 of the 68 participants reported negative effects, largely insomnia, concentration impairment, lethargy and dry mouth. Despite this, nine patients stopped using their other ADHD medication during treatment. Researchers argue that future research should include comparative analysis on patients in the UKMCR while highlighting the need to conduct high-quality random controlled trials for the treatment of ADHD. “This case series is the first of its kind in assessing the clinical outcome of patients from the UKMCR with a primary diagnosis of ADHD prescribed CBMPs for up to 12 months,” authors conclude, adding that the preliminary findings suggest that medical cannabis products may play a role in alleviating symptoms, comorbid anxiety and sleep disruption associated with ADHD.  “CBMPs were well-tolerated throughout this study and the majority of patients (83.82%) did not report any adverse events,” they continue. “Due to limitations in study design, a causal relationship cannot be determined, thus, a definite conclusion cannot be drawn from these results. The findings from this study guide further investigation to assess the therapeutic efficacy and long-term safety profile of CBMPs.”

https://hightimes.com/

Study Finds Medical Cannabis Provides Lasting Benefits for Osteoarthritis Patients

Patients with osteoarthritis reported a reduction in pain associated with the disease when using medical cannabis, according to the results of a recently published study by British researchers.  Osteoarthritis (OA) is a degenerative disease of the joints characterized by the wearing down of cartilage at the ends of bones. The condition is the most common form of arthritis, affecting more than 32.5 million adults in the United States, according to data from the Centers for Disease Control and Prevention. OA occurs most frequently in the hands, knees and hips, causing pain, swelling and stiffness. In extreme cases, OA can cause reduced function or disability, with patients unable to work or perform daily tasks. Because there is no cure for OA, doctors treat the symptoms of the disease with various therapies, including over-the-counter medications and prescription drugs. Weight loss, increasing activity and physical therapy are also commonly employed therapies. In more severe cases, additional strategies including supportive devices such as canes or crutches can be used, as well as surgical options such as joint replacement. In a study published last month in the peer-reviewed Journal of Pain & Palliative Care Pharmacotherapy, a team of British researchers notes that the pain associated with osteoarthritis can be disabling and affect quality of life because of “mood disturbance, interference with social relations, and diminished cognitive function.” However, the opioids and non-steroidal anti-inflammatory drugs (NSAIDs) commonly used to treat OA are not appropriate for long-term use because of potentially dangerous side effects. As a result, the use of medical cannabis treatments is attracting widespread interest among patients and healthcare professionals. In a report on the study, the National Organization for the Reform of Marijuana Laws (NORML) explains that British medical specialists have been allowed to prescribe cannabis-based medicines to patients who have not responded to conventional medications. The researchers investigated the effectiveness of using cannabis-based medicinal products (CBMPs) including flower and oil extracts in a group of OA patients enrolled in the UK Medical Cannabis Registry. The researchers assessed the change reported by participants using medical cannabis over one year. An analysis of the data revealed that patients reported symptom improvements at one month, three months, six months, and at one year, indicating a sustained improvement of symptoms throughout the study. “Commencement of CBMP treatment was associated with reductions in pain-specific PROMs [patient-reported outcome measures] at all time points in patients with osteoarthritis,” the researchers wrote in the study. The researchers documented few serious side effects or adverse events (AEs) associated with cannabis experienced by participants in the study. Most reported side effects were mild or moderate, with dry mouth, drowsiness and constipation being the most commonly reported. “AEs were mainly mild or moderate in severity,”  researchers wrote. “Fatigue was the most common AE in this study.” The authors noted several limitations of the research, including the lack of a placebo group to compare results. Additionally, the “study was subject to significant selection bias because patients received treatment from the same private clinic; hence, inclusion was limited to those who could afford treatment,” among other limitations. Overall, the researchers found that medical cannabis treatments were an effective treatment for OA, with participants in the study reporting reduced pain and better health-related quality of life (HRQoL). Causality could not be established, however, leading the researchers to call for randomized clinical trials (RCTs) investigating the use of cannabis formulations for the treatment of OA. “These results suggest an improvement in pain-related outcomes for patients with osteoarthritis following the initiation of CBMP treatment. Furthermore, there was an improvement in general HRQoL metrics across the follow-up period. CBMPs also appeared to be well-tolerated at 12-month follow-up,” the researchers wrote, adding, “Hence, this study supports the development of RCTs for CBMP use in osteoarthritis.”

https://hightimes.com/

Alaska House Approves Bill To Establish Task Force To Investigate Psychedelic Therapy

On May 2, the Alaska House of Representatives recently approved House Bill 228 in a 36-4 vote, which would establish a task force to regulate various psychedelic-assisted therapies. The official name of the group will be Alaska Task Force for the Regulation of Psychedelic Medicines Approved by the United States Food and Drug Administration. Passing HB-228, according to Rep. Jenny Armstrong who sponsored the bill, is an attempt to get ahead of possible future substance rescheduling and/or federal approval. “This August, it is widely anticipated that FDA will approve the most significant medicine for the treatment of mental health in decades,” Armstrong said prior to the House floor vote. She added that FDA approval of psilocybin as a medical treatment could be coming in the next one to two years. “House Bill 228 before us today would create a task force that would put forth recommendations for the next legislature to consider as it relates to this treatment. Whether you are excited about the idea of psychedelics getting approved, you’re neutral or you’re flat-out against it, I think we can all agree that if it is coming, we should be prepared and be thoughtful in how we approach it.” Armstrong also noted that Alaska not only has the most veterans per capita, but is also ranked among the highest in violence rates throughout the U.S. According to the Federal Bureau of Investigation data spanning 2012-2022, murder and aggravated assault were among the top crimes reported in Alaska. While the total crime rate in 2021 and 2022 was reduced compared to numbers from 2018, murder incidents increased in 2019 and 2022. If passed, HB-228 would require that a task force be established, and for the group to spend one year reviewing the pros and cons of psychedelic-assisted therapies such as psilocybin and MDMA. Most House representatives were receptive to moving the bill forward to assist those who have mental health conditions. Rep. Laddie Shaw spoke up and explained that she was formerly the director of Alaskan Veteran Affairs, and veterans are asking for some kind of positive move forward. “This task force gives us an opportunity to move forward with some productivity on behalf of our veterans,” Shaw explained. “We haven’t done anything for the last 50 years. Let’s move forward with something.” Rep. Sarah Vance also supported the bill, stating that even though she’s uncomfortable with the topic, she still sees the value in exploring psychedelic-assisted therapies as an option. Other representatives, such as Rep. Dan Saddler, opposed the idea that there is any benefit to psychedelic drugs. “I rise against this bill because I don’t believe we should be going off in a direction in what I believe to be a premature fashion,” Saddler said. He added that a task force would encroach “on the purview of the legislature.” Rep. Jamie Allard claimed that military veterans were being harmed by those attempting to promote psychedelic therapy agendas. “Using our military veterans as experiments? We aren’t experiments,” said Allard. “We are human beings who deserve to have things done in the proper manner, and slowly and concisely.” Rep. David Eastman compared the approval of psychedelic medicine to the once normal acceptance of lobotomies. “I look at the history of medicine in this country, and it was not that long ago that we were told—and our entire government, you know, echoed—that lobotomies were a good thing, and they were carried out in our country,” said Eastman. “I hope that we will not look back some number of years now and see that hallucinogens were also a mistake.” HB-228 received amendments one day before the House floor vote. On May 1, one of these changes included adding a board of directors member from the Alaska Pharmacy Association to the task force. Other changes include extending the due date of the task force report from December 31, 2024 to January 31, 2025. The task force was originally set to end at the beginning of the legislative session, but changes altered this timeline so that it would conclude at the end of the session instead. Another amendment required that any task force members from the Alaska State Medical Association must be physicians. “These are all items that we were looking to clean up with the other body if they weren’t tackled today and so I fully support them.” commented Armstrong. The next move is for HB-228 to be presented to the Senate Judiciary Committee on May 6. Senate Bill 166 is a companion bill to HB-228, introduced in January by sponsor Sen. Forrest Dunbar. At a Senate Labor & Commerce committee hearing in February, Dunbar explained the purposes of the bill: “…the overriding purpose of the task force is still the same: We are preparing Alaska—hopefully preparing—for what we see as the very likely legalization, in the medical context, of certain of these substances,” Dunbar said.  Alaska legalized medical cannabis through a voter initiative in 1998, and adult-use cannabis was later passed through a voter initiative in February 2015.

https://hightimes.com/

Psychedelic Pioneer Peggy Mellon Hitchcock Dies at 90

Margaret “Peggy” Mellon Hitchcock, an ultra-wealthy heiress who grew up in the Andrew Mellon estate and its fortunes, funded LSD-fueled adventures for Dr. Timothy Leary and Dr. Richard “Ram Dass” Alpert, passed away on April 9 and an elaborate obituary was written by Penelope Green for the New York Times on May 3. “Pretty Peggy Hitchcock was an international jet-setter, renowned as the colorful patroness of the livelier arts and confidante of jazz musicians, racecar drivers, writers, movie stars. Stylish, and with a wry sense of humor, Peggy was considered the most innovative and artistic of the Andrew Mellon family,” Leary wrote in his 1983 autobiography, Flashbacks. The debut 1974 issue of High Times and April 1978 issue contained excerpts from Leary’s writings. Both psychedelic gurus were kicked out of Harvard: Leary was kicked out of Harvard for allegedly missing teaching responsibilities (but more likely for advocating for LSD), and Alpert was kicked out of Harvard for giving psilocybin to an undergraduate student. In Leary and Alpert’s experiments, including the Harvard Psilocybin Project, graduate students from Harvard and other schools in Boston were given psilocybin and asked to write a report about their trips. In another experiment, they offered psilocybin to prison inmates in the hope it would diminish recidivism. Both LSD and psilocybin were legal at the time, however. They both benefited from Hitchcock’s money and ability to host psychedelic activities, where they continued for about five years. Hitchcock was remembered for being nurturing, but also being a force of nature in the fields she chose to entertain. “She was a vibrant person, very enthusiastic,” her brother Billy Hitchcock told New York Times. “She had a completely open mind. Generous hearted to the point where people could take advantage of her. She had a lot of pain in her life, she was unlucky in love, but you would never know it. She was a real force. Whatever she did, she threw herself into.” The documentary Dying to Know on Netflix, interviews Hitchcock, who discusses her involvement with LSD. Hitchcock tried acid when it was a legal experimental drug. “It really confirmed a lot of things that I had hoped were true, that I had sort of glimpsed at various times in my life, that there was a larger reality than what my everyday, humdrum experiences were,” she said. Hitchcock and her brothers allowed Leary to set up camp at their family estate called Daheim (German for “at home”), also known as Millbrook or the Hitchcock estate. It was built by an early 20th-century resort architect named Addison Mizner. A five-year run of psychedelic adventures ensued, attracting people like Allen Ginsberg, Charles Mingus, and R. D. Laing to join for the ride. The New York Times reports that Hitchcock was at the estate when Ken Kesey and the Merry Pranksters rolled up to the mansion in Furthur, their psychedelic school bus. Leary described it as “a psychedelic summer camp” and it was basically converted into a psychedelic research center as well. Leary rented the 64-room mansion that was owned by Hitchcock’s brothers in Millbrook. He paid $1 per year in rent and turned it into a psychedelic haven and research center. You can see a giant face painted on the side of the mansion during his stay. French Toast reports that Hitchcock also helped fuel the cannabis movement, as she frequented smoke-filled jazz club performances and the psychedelic movement often involved copious amounts of cannabis. The 1960s counterculture movement was very alive, and the mansion served as one of its headquarters. How did she get control of this mansion? Mellow was one of the longest-serving Secretaries of the Treasury and helped shape the Industrial Revolution. In addition, Hitchcock’s grandfather was William Larimer Mellon, a founder of Gulf Oil. Peggy’s mother was a Mellon heiress and her father, Thomas Hitchcock Jr., was a leading polo player and a partner at Lehman Brothers. Standard Oil President Walter C. Teagle purchased an estate in Millbrook, New York and eventually sold it to the Hitchcock family, for whom it’s named today. Heirs to the Mellon fortune—siblings William Mellon “Billy” Hitchcock, Tommy Hitchcock III, and Margaret Mellon “Peggy” Hitchcock—opened the doors of their estate to Leary. Hitchcock married Walter Bowart, a counterculture journalist, who was a founder of The East Village Other counterculture newspaper. In 1966, Bowart testified before the Senate Committee on Juvenile Delinquency and urged the committee members to try LSD for themselves. High Times reprinted several East Village Other articles, such as a reprint of Leary’s 1968 article, “Deal for Real.” Hitchcock bankrolled a publishing house for her husband called Omen Press, which published books on metaphysics and spirituality. They divorced in 1980. Without Hitchcock’s involvement, it’s unlikely Leary and Ram Dass would’ve become the household names they are today.

https://hightimes.com/

Enemies of Weed Legalization Are Already Raising Money To Challenge Federal Rescheduling Effort

Last week, the Drug Enforcement Administration (DEA) shared that marijuana would be rescheduled from a Schedule I, meaning that the plant was classified as a substance with no accepted medical value, such as heroin, to a Schedule III, controlled substances that allow for some medical use, such as ketamine. While cannabis advocates, stoners, and anyone with the ability to reason welcomed this news (although it fell short of actually declassifying or legalizing it), just a day following the DEA announcement, a prominent group opposed to cannabis legalization already sent out an email to its supporters soliciting funds to combat the policy change. “SAM will oppose this change at every level, including, if necessary, pursuing legal action,” the group Smart Approaches to Marijuana shared in the email sent out on Wednesday, which asked, of course, for money.  The email came with a link to what SAM crowned a “Rescheduling Legal Defense Fund,” which seeks either one-time (or you can make that recurring, of course), monthly donations ranging from $250 to $5,000. Think of all the weed you could buy with that money! Loaded anti-cannabis haters also have the option to donate much, much more.  If you’ve heard of SAM before, it’s because they are very vocal about what they perceive as the dangers of marijuana. The landing page on their website shares that they’re apparently trying to prevent the “next Big Tobacco,” which is just plain silly. As High Times reported, a recent study actually found that tobacco consumption has decreased in states with recreational cannabis legalization. SAM’s “About” section claims to be bipartisan and then links out to The Drudge Report.  “Our new Rescheduling Legal Defense Fund will be used to support our challenges of marijuana laws and regulations, specifically marijuana’s Schedule III recommendation,” reads the donation page. “Let’s be clear: this does not mean marijuana is legalized—it will remain federally illegal,” the email reads (yes, unfortunately, they are right about this). “But, if implemented, moving marijuana to Schedule III would give Big Marijuana billions in tax write-offs as well as continue the normalization of high-potency THC drugs. SAM will oppose this change at every level, including, if necessary, pursuing legal action.” They are absolutely right about the tax write-off; it’s one of the biggest wins regarding the descheduling announcement. As business is set up now, it’s incredibly hard for cannabis companies to turn a profit. The National Cannabis Industry Association (NCIA) anticipates that reclassifying cannabis to Schedule III will alleviate some of the harsh effects of tax code 280E on thousands of state-legal cannabis enterprises. The Legal Intelligencer notes that this change would eliminate the current restrictions on tax deductions that 280E imposes.  As for the high THC concern, consuming too much THC can be very uncomfortable, and there are high THC products available for those with high tolerances, but this argument is so tiring. Of course, there’s the obvious comparison to liquor, which leads to blackouts and even death in a way that a big edible just doesn’t. But perhaps more importantly, it’s just so easy to use THC responsibly. One of the benefits of legalization is that products can be clearly labeled so one can purchase the acceptable dose for their tolerance and body weight. There may be 100mg gummies available now, but there are also 2.5mg usually on the same shelf. We know from the failed war on drugs that prohibition doesn’t make things better; in fact, we now know that adult-use cannabis laws and sales were not associated with an overall increase in teen substance abuse. Rather, the researchers found modest drops in alcohol and e-cigarette use occurred. One must use cannabis responsibly, especially when it comes to edibles, but we have to leave that up to individuals and assume that grown-ups can take care of themselves.  SAM’s president, Kevin Sabet, accused the Biden administration of “starting with the decision and working backward to find the supporting materials,” but, in reality, the original decision to classify cannabis as a Schedule I was, as noted by Rep. Earl Blumenauer said in an emailed statement obtained by High Times in our reporting on the descheduling decision, based on stigma rather than science. And, based on the knee-jerk reaction of SAM, a day after the descheduling announcement, we can assume that the modest move to move marijuana to Schedule III will not end this toxic stigma and that the War on Drugs is far from over. 

https://hightimes.com/

Where the Sherbwalk Ends

A fruity yet spicy rendition of Permanent Marker from Pleasant Effects is boosting the profile of the Rhode Island-based grower across the East Coast, as is its eye-catching and artistic packaging including a nostalgic take on a Shel Silverstein classic. Sam, one of the co-founders behind the brand, gained non-cannabis know-how at a local hydroponics company that was designing large-scale hydroponic produce farms. There, he was a head grower, putting together hydroponic systems, but for edible plants. “Growing cannabis is always what I’ve loved to grow the most. I’ve always been passionate about it,” Sam says. “We competed in the East Coast Zalympix in New York City last year, that was definitely one cool moment.” Recently, Pleasant Effects executed a collaboration with The Book Club, which releases curated cannabis drops, all styled after books and designed by glass artist and illustrator Trevor Johns, aka Trevy Metal. The drop with Pleasant Effects was inspired by the whimsical collection of poems by Silverstein, specifically a play on his classic, Where the Sidewalk Ends. “Where the Sherbwalk Ends” is a collaboration with Pleasant Effects, based off of Sherbanger #22, and lists a fictional author, Sherb Silverstein. “We’re pretty much showcasing the love for literature,” says Trevy Metal. “Every book that we chose has somewhat of a nostalgic factor to it. Like this one in particular, I was like a huge fan, as I was inspired by all illustrations from Shel Silverstein growing up.” The homage is fitting given that Silverstein wrote a series of poems and songs about pot, quaaludes, and other drugs. These references can be found in his famous poem “The Smoke-Off” (1978) which describes smoking in San Rafael, California or the song “I Got Stoned and I Missed It” (1972). This article was originally published in the April 2024 issue of High Times Magazine.

https://hightimes.com/

Is Hop Latent Viroid Everywhere?

Hop latent viroid (HLVd) is one of the most devastating things ever to hit cannabis, with researchers estimating it could be costing the industry up to $4 billion per year in financial loss. But are the streets safer than the recreational mega-farms that were decimated in the transition to legalization? We reached out to some hitters from both sides of the fence to see if HLVd has had the same impact on the underground cannabis market that it’s had on the recreational market. For those not in the know, HLVd is one of the worst things to happen to cannabis since the creation of the Drug Enforcement Administration. Currently, the viroid is considered one of the biggest threats to both the global cannabis and hop industries. Viroids are the smallest known infectious agents that can cause diseases in plants. The first viroids were found in potatoes in 1971, and then eventually, HLVd was reported in two out of three varieties of hops in Spain in 1987. Many plants affected by the disease are also asymptomatic, meaning there are no symptoms or signs of infection early on. Later, the viroid will fully express itself and ruin a plant’s yield and vigor. In the case of cannabis, this prevents a plant from reaching its full potential when producing cannabinoids and all the other good stuff. HLVd’s costs to the cannabis industry have now run well into the billions at this point, and it’s fair to think that the loss may even be over $1 billion on the trap side of the market, too. Last year, researchers in Canada and Japan consolidated all the known data about HLVd to get the clearest picture yet. The research, published in the scientific journal Viruses, cited a 2021 survey conducted by Dark Heart Nursery.  Dark Heart’s founder, Dan Grace, was quick to agree with the idea that HLVd had to come out of the trap.  “All the genetics we have now came out of the illicit market, that stands to reason,” Grace told High Times. “It’s just a matter of historical facts. The virus was all over the place way before 2017. I mean, we learned about it in the Emerald conferences. Maybe like [in] 2013, people were calling it PCIA for ‘Putative Cannabis Infectious Agent.’” Grace said people at The Emerald Conference—a cannabis science and psychedelics science event put on by MJBiz Science—were presenting qualitative data at that time when no one knew what HLVd was. Dark Heart’s 2021 survey “showed that it had been growing for years at an exponential rate, as one would expect from a virus,” Grace said, noting HLVd is now everywhere. “But to the question about the illicit market or regulated market, I mean, I guess all I can say is that back when all of us operated in the illicit market, none of us knew what it was or had the resources or anything else to figure out what it is. It’s only with transparency and very transparent, honest communication that we can start to solve the problem.” Dark Heart was one of the first organizations to identify HLVd in 2019. Two years prior, the nursery began working with Dr. Jeremy Warren, who oversaw the study of intentionally infecting healthy plants with HLVd and analyzed the symptoms of sick versus healthy control plants. Warren confirmed that HLVd was the cause of “dudding” symptoms, such as yellowing leaves or stunted growth. Dark Heart research included an examination of 100 California cannabis cultivation operations between August 2018 and July 2021 and discovered that in 90% of those grows, one-third of the plants were infected with HLVd. More research would be necessary to truly understand the scope of HLVd across the thousands of licensed cannabis cultivators in California. Still, it became clear that it was, and continues to be, a serious problem. Many have attempted to cull plants infected with HLVd, but in reality, a grower’s best bet is to start with clean clones from scratch. To do that, companies reach out to specialized nurseries to buy cuttings started from tissue culture that are ultra pristine and free of disease. One of the popular providers of these cuttings is Node Labs in Petaluma, California. Given their expertise on the issue, we asked Node Labs’s co-founder and Chief Business Officer Dan Adler-Golden if he thought the compartmentalization of the trap scene from the legal market makes it safer from hop latent viroid. He argued the opposite. “The trap scene is where hop latent initially thrived and was unknowingly proliferated with some legendary strains for years,” Adler-Golden told High Times. “Because infected plants can be asymptomatic, the lack of information on the viroid combined with minimal screening practices led to widespread contamination among truly elite cuts.” It’s not crazy to think that as California nurseries transitioned to the legal era, the infected mother plants they brought into the newly birthed rec market came from the unregulated market. It’s not like everyone hunted new genetic stock to go legal at the end of 2017. Adler-Golden explained that Sour Diesel was a famed cut known to have been circulated widely after it was infected. “It is only in the last few years that pathogen testing has become widely available, and stock can readily be screened,” he said. We also asked Adler-Golden whether he thought the smaller selection of clones available when the market went rec had the biggest impact on the spread to so many cultivation sites. “When the market initially went rec, there was a brief window of time when many nurseries were operating and even supplying their clones at retail, resulting in lots of great options for consumers,” he replied. “However, pathogen screening was not common practice, so cultivators would inadvertently introduce the viroid into their stock by purchasing clones from different nurseries.” Adler-Golden closed, noting that while general pathogen screening services have improved, there are fewer operating today than a few years ago. It’s very difficult for a professional operation to survive handing out dirty cuts anymore. Popular NorCal cultivator Paki Grower believes small isolated unlicensed grows like his have a slim chance of getting infected. “[In] isolated environments such as homes or small personal gardens, you would think that there’s less possibility if you’re taking your own clones and growing from seed,” Paki Grower told High Times. “That’s very situational because it can jump from room to room and grower to grower so easily. It just depends on who is messing with whose cuts.” Paki Grower noted that a lot of the genetics he works with are sourced directly from Wyeast Farms. Wyeast is testing all of its cuts every few months. In recent years, researchers found that crossing an infected parent with a healthy one can spread HLVd in the seeds. Tests found the viroid on the outer shell of seeds made from infected parents and within the seeds themselves. “Wyeast is testing everything he takes into quarantine, and with guys like him having a large collection of heirloom cuts that he might not be able to replace, it’s that much more important to him,” Paki Grower said. He went on to note that even though he believes he is in a more protected situation, the recreational market is starting to take a better course of action. Things like bleaching tools are an important step, given how easy it is to spread HLVd. Imagine that the first clone you take with a fresh razor is infected; how heartbreaking are those trays of cuts going to be? And part of the problem is just knowing what you’re looking at. It’s difficult to identify HLVd until it’s too late. Testing is cheaper than ever, but you’ll still need a refined eye. “I mean, I guess from a grower standpoint, you’re just going to have to pay a lot of attention to detail in the room,” Paki Grower said. “Yes, things can slip by. They can maybe fail to have been detected. Maybe they can pass testing and be hiding and come up at a later time. So the best thing that growers can do is to make sure that every plant that he has is healthy, and if anything is looking out of health, you need to analyze to make sure that it’s not a number of things that aren’t related to that virus.” Just presuming everything is related to HLVd will make your room susceptible to a host of other issues. You should ensure all those other boxes are checked regularly before presuming your weak crop is infected with the viroid. But if all those boxes are checked, and you believe your room to be pest and stress-free, it might be time to get some testing done. At least that’s more affordable than ever. We asked Paki Grower if he felt there was the same level of fear in the underground economy as the recreational market when it came to HLVd. “It’s funny you say that because I’ve worried about it for the last couple of years a lot. And every time I see a plant that’s in kind of crappy health, it could be a user error, it could be an environmental disadvantage. I’m always stressing out about that, dude. That it could be the viroid,” he replied. But it is admittedly a background concern that pops up instead of a feeling of inherent threat given his practices. “I still don’t feel threatened because I deal with kind of just a very select few cuts, and I haven’t seen it in my area here, but we’re talking about, you know, smaller spaces,” Paki Grower said. “We’re not talking about big facilities with margins.” Paki Grower went on to make another interesting point about the famous strains we no longer see in the marketplace. He believes many of the genetics that wore out over time were victims of HLVd. If anything, it’s pretty clear that HLVd has transcended all types of cannabis cultivation operations regardless of their legality or scale. It comes down to sourcing the genetics you’re selecting for your closet, greenhouse, or warehouse from reputable places and implementing the best practices to keep them free of the viroid. At the very least, it’s cheap enough to quarantine any new cuttings you bring into the mix and get them tested these days. You only need a little tent and an LED panel to keep it away from the rest of the kids. Then, just hope the test is negative for HLVd. Hopefully, as cultivators continue to learn more about the disease, even more cost-effective solutions will be discovered. This article was originally published in the April 2024 issue of High Times Magazine.

https://hightimes.com/

Connecticut House Approves Bill Regulating Hemp Products

The Connecticut House of Representatives this week passed a bill to regulate ingestible hemp products, with lawmakers saying the legislation is necessary to protect the public from the potentially harmful effects of hemp-derived cannabinoids. The House approved the measure, House Bill 5150, by a vote of 130-16 on Tuesday, less than three months after it was introduced in the legislature by the House General Law Committee. The legislation now heads to the Connecticut Senate for consideration. Hemp agriculture and products made from hemp were legalized more than five years ago with the passage of the 2018 Farm Bill by the U.S. Congress. Since then, a multitude of ingestible hemp products, many with intoxicating cannabinoids, have been introduced to the market, with widespread availability at retailers including convenience stores, gas stations and smoke shops. Representative Mike D’Agostino, one of the lead sponsors of the bill, said that legislation is needed to put controls on the unregulated market for hemp-derived cannabinoid products. “We can’t ban them, but we can regulate the hell out of them,” said Democratic Representative Mike D’Agostino, the co-chair of the General Law Committee, according to a report from the Hartford Courant. “We say, OK, those products need to be manufactured in accordance with our standards. They need to be labeled in accordance with our standards they have to be to have disclosures in accordance with our standards.” The legislation would regulate hemp products including THC-infused beverages, limiting the sale of certain products to adults age 21 and older. The bill also redefines and expands the definition of high-THC hemp products, which are more tightly regulated than others. Additionally, the bill establishes a new category of THC “which it classifies as an ‘infused beverage’ and requires it to meet many of the requirements for manufacturers of hemp products,” according to an Office of Legislative Research report cited by CT News Junkie. The legislation sets a uniform potency limit for hemp-derived products of one milligram of THC per serving. Products with more THC per serving than the limit would be classified as high-THC products, which would only be available at medical marijuana dispensaries or licensed cannabis retailers, which were established following the legalization of recreational marijuana in Connecticut in 2021.  The bill also defines unregulated sales of cannabis and hemp products as violations of the Connecticut Unfair Trade Practices Act, a change that makes it easier for the Connecticut Department of Consumer Protection and the attorney general to take unauthorized products off the market. “We need to make sure that the rules are being followed, that there’s not a product out there that is unregulated, that is being sold to minors, that is being sold in convenience stores, that is outside of the strict structures that we created,” D’Agostino said. The legislation includes “provisions that allow towns to now go to court and seek to shutter the doors of these vape shops that are selling cannabis or other stores that are selling illegal cannabis, and the towns can get a piece of the revenue and fines that can be levied with respect to that enforcement,” according to the D’Agostino. “If you’re a town that’s approved legal cannabis, the last thing you want is next door a vape shop that’s selling a competing illegal product,” he added. The hemp product regulation bill also sets standards for the labeling of hemp products and amends some rules governing the cultivation of cannabis by social equity licensees. D’Agostino noted that the laws and regulations governing cannabis products and sales will continue to evolve, just as they have for other regulated products. “The liquor laws have been evolving over time for decades since Prohibition ended. We’re three years into this process,” D’Agostino said. “I’ve said it before, I’ll say it again: We’re going to keep coming back and back in this chamber with respect to our cannabis laws and how they evolve and how we respond to that marketplace and make sure we remain in control of it.” State Representative Dave Rutigliano of Trumbull, the ranking Republican on the General Law Committee, is one of many GOP lawmakers who opposed the legalization of marijuana in Connecticut but voted in favor of the hemp products regulation bill. “It’s already legal. We can’t make it unlegal. So what we’ve decided to do is try to regulate it in a way that makes a safer environment for everyone,” Rutigliano said. “Our goal this year, as it was last year, is to get THC products, intoxicating products out of our supermarkets, convenience stores and gas stations, to put it in a place where it’s regulated, where it’s taxed and controlled.”

https://hightimes.com/

Connecticut House Approve Bill Regulating Hemp Products

The Connecticut House of Representatives this week passed a bill to regulate ingestible hemp products, with lawmakers saying the legislation is necessary to protect the public from the potentially harmful effects of hemp-derived cannabinoids. The House approved the measure, House Bill 5150, by a vote of 130-16 on Tuesday, less than three months after it was introduced in the legislature by the House General Law Committee. The legislation now heads to the Connecticut Senate for consideration. Hemp agriculture and products made from hemp were legalized more than five years ago with the passage of the 2018 Farm Bill by the U.S. Congress. Since then, a multitude of ingestible hemp products, many with intoxicating cannabinoids, have been introduced to the market, with widespread availability at retailers including convenience stores, gas stations and smoke shops. Representative Mike D’Agostino, one of the lead sponsors of the bill, said that legislation is needed to put controls on the unregulated market for hemp-derived cannabinoid products. “We can’t ban them, but we can regulate the hell out of them,” said Democratic Representative Mike D’Agostino, the co-chair of the General Law Committee, according to a report from the Hartford Courant. “We say, OK, those products need to be manufactured in accordance with our standards. They need to be labeled in accordance with our standards they have to be to have disclosures in accordance with our standards.” The legislation would regulate hemp products including THC-infused beverages, limiting the sale of certain products to adults age 21 and older. The bill also redefines and expands the definition of high-THC hemp products, which are more tightly regulated than others. Additionally, the bill establishes a new category of THC “which it classifies as an ‘infused beverage’ and requires it to meet many of the requirements for manufacturers of hemp products,” according to an Office of Legislative Research report cited by CT News Junkie. The legislation sets a uniform potency limit for hemp-derived products of one milligram of THC per serving. Products with more THC per serving than the limit would be classified as high-THC products, which would only be available at medical marijuana dispensaries or licensed cannabis retailers, which were established following the legalization of recreational marijuana in Connecticut in 2021.  The bill also defines unregulated sales of cannabis and hemp products as violations of the Connecticut Unfair Trade Practices Act, a change that makes it easier for the Connecticut Department of Consumer Protection and the attorney general to take unauthorized products off the market. “We need to make sure that the rules are being followed, that there’s not a product out there that is unregulated, that is being sold to minors, that is being sold in convenience stores, that is outside of the strict structures that we created,” D’Agostino said. The legislation includes “provisions that allow towns to now go to court and seek to shutter the doors of these vape shops that are selling cannabis or other stores that are selling illegal cannabis, and the towns can get a piece of the revenue and fines that can be levied with respect to that enforcement,” according to the D’Agostino. “If you’re a town that’s approved legal cannabis, the last thing you want is next door a vape shop that’s selling a competing illegal product,” he added. The hemp product regulation bill also sets standards for the labeling of hemp products and amends some rules governing the cultivation of cannabis by social equity licensees. D’Agostino noted that the laws and regulations governing cannabis products and sales will continue to evolve, just as they have for other regulated products. “The liquor laws have been evolving over time for decades since Prohibition ended. We’re three years into this process,” D’Agostino said. “I’ve said it before, I’ll say it again: We’re going to keep coming back and back in this chamber with respect to our cannabis laws and how they evolve and how we respond to that marketplace and make sure we remain in control of it.” State Representative Dave Rutigliano of Trumbull, the ranking Republican on the General Law Committee, is one of many GOP lawmakers who opposed the legalization of marijuana in Connecticut but voted in favor of the hemp products regulation bill. “It’s already legal. We can’t make it unlegal. So what we’ve decided to do is try to regulate it in a way that makes a safer environment for everyone,” Rutigliano said. “Our goal this year, as it was last year, is to get THC products, intoxicating products out of our supermarkets, convenience stores and gas stations, to put it in a place where it’s regulated, where it’s taxed and controlled.”

https://hightimes.com/

Clinical Trial To Assess LSD Microdosing For PMS

MindBio Therapeutics Corp. said that “MB22001, a proprietary and self-titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take home microdosing” has been approved for take-home use in a pair of clinical trials. “The trials in women’s health aim to address a huge unmet need in effectively treating Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric disorder (PMDD) without the side effects of anti-depressants and the combined oral contraceptive pill often used in treatment,” the company said in a press release. The company “now has in its portfolio, multiple Phase 2B clinical trials underway and in a series of world firsts,” the press release said. “This month, MindBio aims to present secondary data relating to its recently completed Phase 2A trial of MB22001 in patients with Major Depressive Disorder. The Company has already met its primary end-point using the global standard Montgomery-Asberg Depression Rating Scale (MADRS) to show a 60% drop in depressive symptoms and 53% complete remission from depression by week 8 of treatment,” the company said in the release.  “The secondary data presentation will report on post treatment effects, using the MADRS and several other vital clinical scales for measuring the effects of MB22001 on each clinical trial participant’s mental health. The readouts are important to understanding the full impact on patients of this novel medicine and if the results continue to be positive, strengthening the position of this drug as it progresses towards Phase 3 clinical trials.” As Benzinga explains, MindBio’s thesis “is that it can be used acutely during specific periods of the menstrual cycle, with targeted dosing to treat negative mood symptoms.”  “This thesis is based on three main facts a) The acute dose day mood-elevating effects of MB22001 have been demonstrated in MindBio’s Phase 1 trials b) MindBio’s Phase 2a open-label trial in depressed patients show long-term improvements in mood and c) reports in the grey literature of people self-medicating for PMS/PMDD using LSD microdoses,” Benzinga said. “Premenstrual syndrome (PMS) is estimated to affect ~25% of all women who menstruate – equivalent to 956 million women worldwide. A particularly severe form of PMS is termed premenstrual dysphoric disorder (PMDD) which affects 3-8% of women who menstruate. Current treatments for these issues are selective serotonin reuptake inhibitors (SSRIs), given either continuously or daily during the luteal phase of the menstrual cycle. While SSRIs can be effective for some with PMDD approximately 40% of women with PMDD do not respond to SSRIs, and common side effects of SSRIs when used for PMDD include nausea, decreased energy, somnolence, fatigue, decreased libido and sweating.” MindBio bills itself as a “pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions,” and that invests in “clinical research to discover potential new treatment options and we aim to create novel medicines and treatment regimes from breakthrough microdosing studies.” The company provides more background on this year’s clinical trials of MB22001. “Phase 2a clinical trials completed in March 2024 using MB22001 in Major Depressive Disorder.  The Phase 2a clinical trial resulted in 53% of depressed patients entering the trial being in complete remission after 8 weeks of treatment. Overall, there was a 14.1 drop in MADRS Score (Montgomery-Asberg Depression Rating Scale). The MADRS is a global standard for measuring the severity of Clinical Depression. Overall there was an impressive 60% drop in Depressive symptoms at week 8 of the trial,” the company explains, adding that it has “just started dosing in a Phase 2b depression trial.”   “In this randomised active placebo-controlled trial, 90 patients with Major Depressive Disorder will be given microdoses of MB22001 or an active placebo over an 8 week period.  At the end of the 8 weeks, all participants in the placebo and drug group will be offered an 8 week extension to ensure the placebo group has the opportunity to trial MB22001,” it continues. “A second Phase 2b trial in late stage cancer patients is also currently underway.  This cancer study will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted Meaning-Centred Psychotherapy to standard Meaning-Centred Psychotherapy in people who have advanced cancer and anxiety or depression.” Participants in the trials “will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo,” MindBio said.  “The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. Our findings will inform the development of a larger trial and provide an initial indication of the potential benefits of psychedelic microdosing in advanced cancer.”

https://hightimes.com/

Survey: High-THC Flower Yields Few Serious Side Effects in Patients

Findings published in the journal Pharmacopsychiatry, based on an online survey conducted in Germany between June 2020 and August 2020 with more than 1,000 patients, debunked the claim that high-THC cannabis poses unique health risks. “Patients were allowed to participate only if they received a cannabis-based treatment from pharmacies in the form of cannabis flowers prescribed by a physician,” the researchers explained.  “Overall, the mean patient-reported effectiveness was 80.1% (range, 0–100%). A regression model revealed no association between the patient-reported effectiveness and the variety. Furthermore, no influence of the disease on the choice of the [medical cannabis] strain was detected. On average, 2.1 side effects were reported (most commonly dry mouth (19.5%), increased appetite (17.1%), and tiredness (13.0%)). However, 29% of participants did not report any side effects. Only 398 participants (38.7%) indicated that costs for [medical cannabis] were covered by their health insurance,” they continued.  The researchers said that patients “self-reported very good efficacy and tolerability” of medical cannabis, and that there “was no evidence suggesting that specific [medical cannabis] strains are superior depending on the disease to be treated.” The findings are notable given that in Europe “pharmaceutical-grade cannabis flower…contain THC levels of 20 percent or greater,” according to NORML. NORML said that the survey’s findings “push back against claims that cannabis strains higher in THC pose unique risks to health or that there is an absence of research supporting the efficacy of medical cannabis chemovars above 10 percent THC.” The researchers behind the survey said that they were driven to examine the matter due to the lack of research containing high-potency medical cannabis. Their findings, they said, represent “the first large study exploring the effectiveness and tolerability of different cannabis strains prescribed by physicians in Germany.” “There is increasing evidence that cannabis-based medicine (CBM) is efficacious in many different indications, mainly chronic pain, spasticity in multiple sclerosis, and palliative care. After reintroduction in medicine, the number and type of available CBM constantly increased, ranging from pure tetrahydrocannabinol (THC) to pure cannabidiol (CBD), as well as cannabis extracts and flowers with very different THC:CBD ratios. In Germany, cannabis flowers and extracts were legalized for medical purposes in 2017. In limited exceptional cases and after approval (according to the Social Insurance Code), costs are covered by health insurance. Today (as of 2023), in Germany, more than 150 different cannabis flowers can be prescribed. However, it is largely unknown, whether particular strains and/or different concentrations of THC, CBD, other cannabinoids, and further ingredients, including terpenes and flavonoids, result in different effectiveness in different conditions,” they said. “So far, only a limited number of studies directly compared the effects of different cannabis strains in different indications. According to data collected between 2009 and 2010 from 600 patients registered with the Vancouver Island Compassion Society and treated with medicinal cannabis (MC), the ‘more popular’ Cannabis indica strains more effectively relieved pain compared to C. sativa strains. Several characteristics were found to be similar for both species, e. g., trust in purity, route of administration, and reason for use (recreational vs. medicinal).” Still, the researchers also noted limits to their findings, and cautioned against drawing too many sweeping conclusions. “We failed to confirm our main hypothesis that specific cannabis strains are more efficacious in specific indications. There was also no influence of the respective indication on the choice of the MC strain,” they said. “Besides one strain, all strains preferred by participants were THC dominant with high THC concentrations. Self-reported effectiveness and tolerability of MC for the treatment of a variety of medical conditions were rated as excellent, with no relevant differences between C. sativa, indica, or hybrid. The majority of patients had used cannabis as a self-medication as well as MC prescribed by physicians for years. The overall profile of smell and taste was rated as very good. On the other hand, average cost-effectiveness was rated as poor, which is probably because the majority of patients did not get cost coverage from their health insurance.” Other limitations include of the study include “(i) only German-speaking patients could be included, (ii) most participants came from Germany, and thus data represent only a small geographical region, (iii) only data for MC strains available in German pharmacies in 2020 could be collected; (iv) data were collected online based on self-reported diagnoses and treatment effects, (v) it cannot entirely be excluded that participants provided untruthful information.”  But the study also “has several strengths,” they said, noting its “large sample size…relatively short recruitment time…inclusion of only patients that used MC from pharmacies prescribed by physicians…patients with a wide spectrum of different indications…relatively long time use of MC…and use of 5.9 different MC strains on average allowing comparison with respect to clinical effectiveness.” 

https://hightimes.com/

Friends Don’t Let Friends Jump Through Loopholes

If you woke up from a decades-long coma or were dropped onto Earth by aliens, you’d be forgiven for assuming that weed is legal in the United States. It seems like every gas station, corner store, and smoke shop from Miami to Montana is ready to get you some kind of stoned whenever you’d like. Gummies, vapes, pre-rolls, it’s all there with neon weed leaves in the window.  Of course, cannabis is not legal in the United States. Despite plenty of regulated and taxed state-legal weed sales, the plant is still a Schedule I narcotic in the eyes of the federal government. Hemp, on the other hand, is so legal that you can run it through chemical extractions to synthesize minor cannabinoids, turn it into oil and spray it all over gummies, and hemp pre-rolls and pack it into vape carts and sell it anywhere you want. Delta 8, Delta 10, HHC, THC-O, THCP, and the rest of the hemp weed pretenders have popped up everywhere for one simple reason: people like to get high and they’ll often take the most convenient and cheapest route to that elevated destination. But as we look forward to a time when weed – real weed – will be legal nationwide, we should already be establishing norms for cannabis that push back firmly against the products of hemp bill loopholes, no matter their legal status. When the 2018 Farm Bill was signed into law it legalized hemp – defined as any cannabis plant or product that tests at levels lower than 0.3% Delta 9 THC – and set the stage for the eruption of the CBD market. It seems like a lifetime ago now, but CBD edibles, mints, salves, ice creams, lattes, and bottled water were everywhere for a couple of years, advertised as a super supplement that could do everything to make you feel better…except get you high. That was a problem. People got tired of paying $20 for a pint of CBD ice cream or $12 for a CBD latte that didn’t get them high. They wanted to get high. No worries, the loopholes in the Farm Bill are big enough to fit a Mac truck, it could certainly accommodate a little intoxication. So the hemp green rushers with thousands of acres of plants and vats of CBD extract started getting creative, remixing the CBD with solvents, converting the chemical makeup through isomerization, and spitting out chemical cousins of THC. Delta 8, HHC, THC-0, THCP, the list goes on. They get you high and they’re below the 0.3% THC legal limit, problem solved. With convenience retailers across the country already used to hawking CBD in every form factor imaginable, the switch to hemp-derived was seamless. And while you, dear High Times reader, likely know better and prefer real weed derived from real weed, there are plenty of people who see weed leaf packaging and the letters THC at the register and see no difference.  Not only are these minor cannabinoid products synthetically derived from industrial hemp, but they are done so with no oversight, regulation, or consumer protections. From contaminations in the production process to mislabeled products that contain much less or much more cannabinoids than advertised, there is no telling what you’re actually getting when you buy hemp-derived cannabis products. Those certificates of authenticity and lab reports that you can find online? Those are really easy to fake.  As we’ve seen with synthetic weed aka spice, vitamin e-tainted vape carts, and bogus psilocybin chocolates, if the only goal is to get you high as cheaply and conveniently as possible, bad actors will thrive.  In an interview with Chemical & Engineering News, Christopher Hudalla, president and chief scientific officer at analytical testing firm ProVerde Laboratories said that after thousands of tests of products labeled as Delta-8 he was horrified at “consumers being used as guinea pigs.” “My concern is that we have no idea what these products are,” Hudalla said. “So far, I have not seen one that I would consider a legitimate delta-8-THC product, there’s some delta-8 in there, but there’s very frequently up to 30 [chromatographic] peaks that I can’t identify.” We have arrived at a point in American culture where it is socially acceptable to sell intoxicating products labeled as weed on gas station counters, and so as real weed continues to legalize state-by-state and eventually nationwide, it will be on the cannabis culture to push back, not only to make sure our fellow consumers are safe, but also to make sure that real weed growers and sellers – legal and illegal alike – can continue to survive in the changing industry. From stoners to cannabis brands and figures in the culture to pro-legalization lawmakers, we need an all-hands-on-deck push back against loophole weed. Make sure your once in a blue moon smoker friends know the difference, make sure your parents know the difference, make sure your customers know the difference, and no matter how economically appealing it may be to jump at the bag of money, don’t put your weed brand’s logos on Delta 8 vapes to cash in at corner stores.  Cannabis has always been about more than just getting high – especially when the one note high from Delta 8 is unreliable and simply not the same – it’s about exploring the plant’s expressions through terpenes, cannabinoids, and the people that make it possible.  Buying real weed is easier and cheaper than ever before. There are delivery services in every major city, not to mention some form of legal dispensary, unregulated bud boutique, or good old fashioned weed dealer open in every zip code in the country – handing any part of the market over to faceless edible and vape companies turning industrial hemp CBD extract into unrecognizable synthetic cannabinoids doesn’t do anyone any good. Mids, exotics, outdoor, deps, indoor, new strains, old strains, brick weed full of seeds and stems – we deserve a weed industry, culture, and public reputation that centers the plant and rejects Delta 8 and its frankenstein synthetic cannabinoid cousins. 

https://hightimes.com/

Hemp Clothing Market to Hit $23B by 2031, Report Predicts

Hemp clothing is making a comeback, marking the hemp textile industry’s latest resurgence in the clothing sector. Researchers say the reasons for the surge include hemp’s notable sustainable and eco-friendly characteristics, and its return on investment. According to a March 26 press release, Allied Market Research, the hemp clothing industry is on a trajectory showing steady growth into the next decade. The global hemp clothing market size was valued at $2.29 billion in 2021, and is projected to reach $23.02 billion by 2031, growing at a compound annual growth rate (CAGR) of 27.1% Allied Market Research analysts explained the factors that make hemp an attractive investment in 2024, besides being a breathable and durable fiber. “Hemp fabric requires less water, chemical fertilisers, pesticides, and herbicides than other fabrics,” the report reads. “It has a lower carbon footprint than many other crops because it is effective at removing carbon dioxide from the environment. In a growing season, one acre of hemp will absorb 10 to 15 tonnes of CO2, which is equal to the typical annual CO2 output of one person.” There are more reasons hemp is more eco-friendly than alternative textiles, which includes the beneficial uses of hemp seed as well. “Hemp is up there on the list of eco-friendly textiles and fibres with jute, organic cotton, flax (linen), and bamboo,” the report continues. “Animal bedding and insulation can be made out of hemp fibre from the stem and hemp seed, respectively. Hemp is also good for the soil. If hemp was originally planted in a field, the production of maize from that field will be higher. Following the harvest of hemp, it’s also a good idea to sow wheat and barley. Some producers are trying to get hemp and cannabis growing certified as organic because of all the potential environmental advantages.” “According to studies on consumer behaviour, between 2000 and 2014, the average customer purchased 60% more clothing, yet they only maintained each item for half as long,” the report continues. “The sobering facts showing the amount of pollution and harm to our rivers, oceans, and atmosphere the fashion industry is responsible for have been in the spotlight. An estimated truckload of used clothing is burned or dumped every second. Many residents are worried, yet the cost and time commitment of the present sustainable fashion solutions are substantial.” Allied Market Research was founded in 2013, offering high-quality syndicated and customized market research reports, consulting services, and insights into leading market players, startups, investors, and stakeholders. The numbers overlap, and are similar to predictions about the hemp fiber industry overall. The Business Research Company’s “Hemp Fiber Global Market Report 2024” was published on March 8 and provides a comprehensive source of information that covers every facet of the market. According to the TBRC’s market forecast, the hemp fiber market size is predicted to reach $50.38 billion in 2028 at a CAGR of 35.0%. The growth in the hemp fiber market is due to increasing legalization to cultivate industrial hemp. Asia-Pacific region is expected to hold the largest hemp fiber market share. Major players in the hemp fiber market include Shenyang beijiang, BaFa Holding BV, Plains Industrial Hemp Processing Ltd., Industrial Hemp Manufacturing LLC, Hemp Oil Canada Inc. The hemp fabric industry was alive and well centuries ago, and came in waves. Textile World called hemp “one of the original textile outputs,” where it flourished for centuries. Hemp fabric gained popularity as early as 4,000 BC (or earlier) in Asia. And then it was a staple clothing textile until being dethroned by Indian cotton around the 13th century. Hemp—despite having no psychoactive effects—got lumped with marijuana as the plant was demonized in the U.S. throughout the past, particularly in the 1930s. Industrial hemp saw a resurgence when it was formally relegalized in the United States with the signing of the 2018 Farm Bill. The bill removed industrial hemp from the list of banned substances in the Controlled Substances Act (CSA). The effort to legalize hemp kicked off in 2014 with several bipartisan legislators initiating a push for the legalization of industrial hemp with a series of legislative efforts.  Section 7606 was included in the original 2014 Farm Bill, which allowed the creation of state-led pilot programs and sanctioned the investigation of hemp for varied commercial and industrial applications. Kentucky was the first state to institute a hemp pilot program under this new legislation. The 2018 Farm Bill formally made commercial production of hemp legal.  Hemp as a fiber presents a safer investment versus hemp-derived cannabinoids, which are facing a series of legal challenges state by state, as legal loopholes in the Farm Bill paved the way.

https://hightimes.com/

Ohio GOP Lawmakers Debate Adult-Use MJ Priorities, Eye June for Regulation Approval

Ohio became the 24th state to allow adult-use cannabis when state voters approved Issue 2 back in November 2023, though advocates and news outlets were quick to highlight GOP lawmakers in the state who immediately sought to amend the newly passed law. And more than five months later, it appears that Republican lawmakers are still grappling with potential changes and regulatory updates to Ohio’s legalization law. While it could shift depending on how lawmakers proceed, currently recreational sales are expected to begin in September, according to a WCMH-TV report. Lawmakers are looking into passing legislation that could jumpstart sales this summer, though it’s ultimately dependent on Republican legislators finding common ground to push the regulatory framework forward and approve it. Namely, the state’s Division of Cannabis Control (DCC) has created a plan to begin granting dual licenses to existing medical cannabis operators to start serving adult consumers early this summer. “I am, I would not say optimistic, but I am reasonably hopeful, if you need words, that we can get something done by June,” Senate President Matt Huffman (R-Lima) told the TV station. While jumpstarting sales in the state is a priority, lawmakers are still in disagreement regarding what rules should be in place prior to a recreational market launch. The original legislation would have allowed adults over 21 to legally buy and possess up to 2.5 ounces of cannabis and grow up to six plants a person, or 12 plants per residence, at home where at least two adults reside. It would have imposed a 10% tax on cannabis purchases to go toward administrative costs, addiction treatment, municipalities with dispensaries and social equity and jobs programs. It’s currently unclear exactly how the future legislation will pan out, though leaders have discussed altering tax revenue distribution, scaling back home cultivation rules and restricting public smoking, among other details. Speaker of the Ohio House Jason Stephens (R-Kitts Hill) noted that many members have varying priorities, affirming that it’s “all about building a consensus.” Stephens highlighted revenue as a main concern, specifically knowing how much money the state could make and ensuring it’s going to the right places. “There’s estimates,” Stephens said. “But we’ve seen estimates before whether it’s gambling or other revenue services that were going to be X and turned out they would be Y… What is the exact amount of taxes, what does that add up to, how does that compare, how much flexibility do local communities have?” Huffman also highlighted the issue of public cannabis smoking, calling it the “most pressing.” Regarding home grow provisions, the Senate passed a bill to add guardrails and immediately offer cultivation for residents, though the House still hasn’t held a hearing on the Senate’s proposal. In the meantime, representatives have worked on their own bill. The House is also in the process of creating a bill to expunge cannabis records. “As we go into the future there will continually be changes and tweaks to recreational marijuana in Ohio,” Stephens said. “I think most reasonable people, including people in the industry, believe that it would be better to have it clarified in law,” Huffman added. Despite his personal opposition to the voter-passed ballot initiative, Gov. Mike DeWine (R) previously passed legislation with the goal of expediting recreational cannabis sales, though he has indicated that he’s more concerned with regulation of psychoactive hemp-derived cannabinoid products. While legislation is in the works, lawmakers have yet to introduce a formal bill on the matter. “This is time for the legislature to move,” DeWine said. “We can’t do it ourselves.” Regarding the disagreement between Republicans in revising the state’s new cannabis law, DeWine previously said he’s “not going to get into that.” Previously, DeWine referenced the disconnect between legalizing cannabis without having regulations in place, leaving consumers without a legal avenue to purchase recreational weed, characterizing the situation as “goofy.”

https://hightimes.com/

Taylor Swift Puts Narcotics Into All of Her Songs on ‘The Tortured Poets Department’

In the opening verse of The Tortured Poets Department, her 11th studio album, Taylor Swift sings that she was a functioning alcoholic until nobody noticed her new aesthetic.  They do now.  In the album, a sprawling 31 tracks (that’s her signature 13 backward), Swift is the most unmasked (and turned on) she’s ever been. She’s done impressing the “wine moms” (even if the blood of fermented fruit is her drug of choice). Sung in a low register, the first 16 songs of TPD are primarily dark, twinkling synthy pop tunes, primarily written with long-term collaborator Jack Antonoff, with help from Aaron Dessner of The National. Dessner, whose Swift collabs are more of the folk music, indie variety, primarily encompass the latter half of The Tortured Poets Department: The Anthology, a surprise bonus album dropped shortly after listeners finished streaming the original album at midnight (shout out to everyone else who got a notification from Spotify that they were in the first ten percent of streams).  TPD racked up 891 million streams in its first week in the United States, setting a new record that surpasses the previous high of 746 million streams, achieved by Drake’s 25-track Scorpion in 2018.  On the title track, “The Tortured Poets Department,” Swift sings about a love interest who “smoked and ate seven bars of chocolate.” Despite acknowledging that this person isn’t Dylan Thomas, and she isn’t Patti Smith (“This ain’t the Chelsea hotel, we’re modern idiots”), Swift is unabashedly captivated, which is why it’s so heartbreaking when deeper into the anthology side of the album, she’s realizing that this person needed her but needed drugs more.   If the tabloids are to be believed, the “tattooed golden retriever” in question is the problematic charismatic Matty Healy of The 1975, who’s openly discussed seeking treatment for a heroin addiction. On “The Alchemy,” she finds a new lover who is into heroin, but this time, with an “e,” (heroine). It’s easy to simply say that she’s singing about drugs on TPD because she was linked to Healy in 2023 when it was primarily written, but looking to tabloid reports on her dating history to explain songwriting decisions is so tired. And, plus, while their recent “situationship” is captivating TikTok, the pair have at least known each other and supported one another’s work for a decade.  So why is Swift getting so real and singing about the munchies and balancing love and addiction now? Is it that cannabis, set to be declassified, isn’t as shocking as it was when she was first involved with bad boys? No.  It’s actually not the first time she’s covered substance use disorders; 2020’s “This Is Me Trying,” as discussed in Folklore: The Long Pond Studio Sessions, is about exactly that. Just no one noticed her new aesthetic! And now she’s totally out of fucks, even if she’s dropping the f-bomb more regularly than ever before. It’s not just drugs. TPD is not just love song after love song about an ex, as many reviews would have you believe. There’s line after line dissecting religion. She’s critical of her seemingly picture-perfect family, perhaps most shockingly, and even her fans.  She’s levitating down the street in “Who’s Afraid of Little Old Me?” like some vampire defanged to perform in the circus (The internet wants to know: Is she beefing with Olivia Rodrigo? What about the diss track allegedly about Kim Kardashian? You fools, if anything, she’s drumming up drama for Reputation: Taylor’s Version!). She’s very horny on “Guilty As Sin?” which continues the album’s investigation into sex and religion. She’s watching American Pie on the garage rock “So High School.” Post Malone contributes smokey vocals on “Fortnight,” and in the video, we get to see what Swift looks like with face tats. The whole thing is honestly a stoner’s delight. And it’s definitely an album for people in their 30s. On “Florida!!!” featuring Florence Welch, which is basically about escaping to the state to dispose of bodies, those that have been on top of you, Swift is observing that her friends “all smell like weed or little babies,” and on the gorgeous “Robin” she’s begging a lover to take her higher and higher while cackling “you look ridiculous,” like she’s Alabama from True Romance in the scene where she kills James Gandolfini with the help of hair spray. “I Can Do It With A Broken Heart” is pop perfection, and Swift singing about crying a lot while remaining productive is as on-brand as it gets. This song will definitely be performed at the remaining 2024 Eras tour dates.  Plus, we get to hear Swift sing the word “daddy” again. The stuff about the exes is largely interesting for Easter Eggs-obsessed fans (The Tortured Poets Department came out on April 19, the day before 4/20, but also the date that, in 1775, the Revolutionary War began as America declared its intentions to leave Britain, and both Healy and her ex of six years who apparently wanted to de-jewel her, are British). The track “So Long London” brings Miss Americana back home. What’s next, the critics and fans want to know. After seeing a video on IG of her singing along to Garth Brooks’s iconic “I’ve Got Friends in Low Places” at a football game, I’m personally crossing my fingers that, as the country genre has become surprisingly cool in recent years, thanks to stars like Kacey Musgraves, who often sings about cannabis, as well, of course, as Beyoncé’s Cowboy Carter and Swift collaborator Lana Del Rey’s forthcoming country album, Lasso, that Tay Tay will go back to her Tim McGraw lovin’ roots, and we’ll eventually get another country album. 13/10 stars for The Tortured Poets Department. 

https://hightimes.com/

Study: Psilocybin Enhances Meditation

According to new research published in the journal Scientific Reports, psilocybin can boost insightfulness during meditation. The study explored, for the first time, “a dataset of functional magnetic resonance images collected during focused attention and open monitoring meditation before and after a five-day psilocybin-assisted meditation retreat using a recently established approach, based on the Mapper algorithm from topological data analysis,” the researchers wrote in the abstract. “After generating subject-specific maps for two groups (psilocybin vs. placebo, 18 subjects/group) of experienced meditators, organizational principles were uncovered using graph topological tools, including the optimal transport (OT) distance, a geometrically rich measure of similarity between brain activity patterns,” the researchers wrote. “This revealed characteristics of the topology (i.e. shape) in space (i.e. abstract space of voxels) and time dimension of whole-brain activity patterns during different styles of meditation and psilocybin-induced alterations.” Perhaps most striking of all, the researchers “found that (psilocybin-induced) positive derealization, which fosters insightfulness specifically when accompanied by enhanced open-monitoring meditation, was linked to the OT distance between open-monitoring and resting state.” They said that the “findings suggest that enhanced meta-awareness through meditation practice in experienced meditators combined with potential psilocybin-induced positive alterations in perception mediate insightfulness.”  “Together, these findings provide a novel perspective on meditation and psychedelics that may reveal potential novel brain markers for positive synergistic effects between mindfulness practices and psilocybin,” they wrote. The research was based on findings involved with 36 “experienced meditators,” who “completed two fMRI brain imaging sessions one day before and after a 5-day psilocybin-assisted meditation retreat following a double-blind, randomized, placebo-controlled, parallel-group study design.” “Placebo or psilocybin (315 body weight; absolute dose, 21.82±3.7 mg) was administered on the fourth day of the retreat, and the 11D-ASC questionnaire for ratings of altered states of consciousness (see Methods ) was administered 360 minutes after drug intake as a retrospective measure of subjective effects. Each scan session (one day before and one day after retreat) consisted of 21 min of resting-state, focused attention, and open monitoring sequences (fixed order), with each meditation lasting 7 min. For each subject both scan sessions were concatenated (with transition times excluded) and Mapper shape graphs were generated and analyzed,” the researchers explained. They concluded that “compared with meditation alone, psilocybin alters the perception of the external world, presumably by increasing informational richness, which is reflected by increased OT distances between OM and RS postretreat.”  Berit Singer, one of the study’s lead authors, explained the inspiration behind the researcher. “I was interested in the technical part of the topic, because I am fascinated by how pure mathematics, especially topology, can be applied to extract important information from latent structures in data that is not apparent to other methods,” Singer told the outlet PsyPost. “Psychedelic neuroscience and mediation is particularly interesting to me, because I can see that there is a lot of research needed to better understand the mechanisms of these substances and techniques, and because I wish that this will help to use them in a beneficial way for individuals and society.” ““It surprised me that the subject-specific Mapper graphs were at first sight very different and did not seem to share many similarities, but when described and simplified using suitable graph measures (the optimal transport distance and centrality) their common structure was revealed and turned out to be quite stable across both groups,” Singer continued. “In other words, their common features were not obvious to spot by eye from looking at the subject-specific Mapper graphs, but only after calculating their topological features.” Singer and the rest of the research team noted in the study that “meditation and psychedelics have attracted increasing scientific interest in recent years.”  “While research on the neurophysiology of meditation and psychedelics has grown rapidly, these topics have been studied mainly from the perspective of functional connectivity, resting-state networks, and signal variability, including measures of entropy and criticality. This article targets an alternative approach in which a novel topological data analysis (TDA) method is applied to the neurophysiological study of the synergistic effects of meditation and psychedelics,” they said. “Meditation can be understood as a form of mental training with various aims, including improving cognitive and emotional self-regulation13, changing attitudes toward the self and others, including their underlying duality, and cultivating positive emotional states. Different types of meditation can be distinguished. Within the attentional family of meditation, two well-researched attentional practices are focused-attention (FA) practices and open-monitoring (OM) practices. FA involves narrowing of the attentional scope. OM, in contrast, involves releasing attentional control and bringing awareness to moment-to-moment experiential content. Psychedelics are a broad class of consciousness-modulating substances that induce altered states of perception, cognition, emotion, and the sense of self. Classical serotonergic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline, and N,N-dimethyltryptamine (DMT).”

FAQ: How to use this hemp news hub

What topics does Chow420’s hemp news cover?

We aggregate and surface reputable coverage on hemp laws and enforcement, THC thresholds and policy proposals, cannabinoid products (CBD/Delta-8/hemp-derived THC), compliance, lab testing, recalls, and broader industry news.

Is this legal advice?

No. This page is for news and education. Hemp rules can change quickly and vary by state—always verify against the latest official guidance and consult qualified counsel for compliance decisions.

How do I evaluate hemp product safety claims?

Look for current third‑party COAs (Certificates of Analysis), clear ingredient labeling, and transparent sourcing. Be cautious with vague potency claims or missing lab reports.

Why do some articles mention Delta‑8 or “hemp-derived THC”?

These products often sit at the center of policy and enforcement changes. We track major updates so shoppers and brands can understand evolving requirements and market impacts.

How often is the news updated?

The crawler is scheduled to run daily. New items appear as sources publish updates.